Introduction
============

*Stenotrophomonas maltophilia* is classified by the World Health Organization as one of the leading multidrug resistant organisms in hospital settings, and an increasing infection rate has been reported in worldwide and nationwide surveillance studies during the past 15 years ([@B15]; [@B5], [@B6]; [@B30]; [@B38]; [@B7]). Treatment of *S. maltophilia* infections is limited due to the extensive resistance displayed to most clinically used antimicrobials, and sulfamethoxazole/trimethoprim (SXT) is the only recommended first-line antimicrobial. However, its use is limited by a high incidence of allergic reactions, intolerance, and increasing resistance mediated by the spread of *sul1* and *sul2* genes ([@B37]; [@B20]; [@B7]; [@B45]). Tigecycline has been reported to retain good *in vitro* activity against *S. maltophilia* in worldwide surveillance and multicenter studies, and [@B40] reported that 80.4% of clinical isolates in China, and 72.7% of SXT-resistant isolates were susceptible to tigecycline, making it a promising alternative antimicrobial for infection treatment ([@B34]; [@B27]; [@B39], [@B40]). Clinical studies revealed the similar effectiveness of tigecycline and SXT in the treatment of nosocomial *S. maltophilia* infection ([@B36]; [@B43]). Therefore, tigecycline could be used for treatment of *S. maltophilia* infection, but invalid use and overuse of tigecycline might result in emergence and spread of resistance during treatment. At present, the tigecycline resistance mechanism in clinical isolates is unclear, and epidemiological surveys focused on frequency and genetic determinants of tigecycline resistance are needed in clinical isolates of *S. maltophilia*. These epidemiologic data could help to guide the appropriate use of tigecycline and preventing the occurrence and spread of multidrug resistance.

Resistance to tetracycline in Gram-negative bacteria is usually attributed to two different mechanisms: acquisition of tetracycline-specific resistance genes and increased expression of intrinsic multidrug resistance efflux pumps ([@B3]; [@B26]; [@B7]; [@B33]). For tetracycline-specific resistance genes, carriage of the flavin-dependent monooxygenase genes (*tetX*, *tetX1*, *tetX2*) could confer resistance against tigecycline ([@B3]). The *tetX1* gene has been detected in tigecycline-nonsusceptible *Acinetobacter baumannii* isolates in China, indicating that the *tetX1* gene might play a role in the reduced tigecycline susceptibility in clinical *A. baumannii* isolates ([@B14]). The other tetracycline-specific genes, including that encoding for efflux pumps (*tetA*, *tetB*, *tetH*, *tet39*) and ribosomal protection proteins (*tetM*), were also commonly detected in Gram-negative bacteria, but their detection rate and potential role in mediating tigecycline resistance in *S. maltophilia* has not been investigated ([@B3]; [@B26]; [@B7]). A variety of intrinsic efflux pumps were presented in *S. maltophilia* and the resistance-nodulation-cell division (RND) family were recognized as the most important intrinsic multidrug-resistance efflux pumps ([@B7]). The K279a sequence carries nine RND-type efflux pump genes ([@B12]). Six of these efflux pumps have been characterized, among which SmeDEF, SmeIJK, SmeOP-ToICsm, and SmeVWX can confer resistance to tigecycline or tetracycline ([@B2]; [@B44]; [@B9]; [@B18]; [@B24]; [@B7]; [@B31]). Besides these RND efflux pumps, SmrA, a member of the ATP binding cassette family, confers resistance to fluoroquinolones and tetracycline ([@B1]). However, most of these studies were performed by genetic introduction, deletion, or mutation in a single reference or clinical strain, and could not be representative of the common clinical scenario. Though all of these intrinsic efflux pumps could mediate tigecycline resistance, which is the predominant genetic determinant in clinical strains is still unclear. Therefore, molecular epidemiological investigations on the tigecycline resistance genetic determinants in clinically isolated *S. maltophilia* are still needed.

To this end, we investigated the frequency and antimicrobial susceptibility of 450 clinical isolates of *S. maltophilia* obtained between 2012 and 2015 from three university hospitals in Beijing, China, and further explored the possible genetic determinants of tigecycline resistance. We compared the detection rate of various tetracycline-specific resistance genes by PCR and the expression levels of multidrug-resistance efflux pumps by real-time PCR in tigecycline-nonsusceptible strains (TNS, minimum inhibitory concentration \[MIC\] for tigecycline \> 2 mg/L) vs. tigecycline-susceptible strains (TSS, MIC for tigecycline ≤ 2 mg/L). The epidemiological investigation of the resistance profile and resistance genetic determinants to tigecycline could aid in the rational use of tigecycline and help in the development of targeted prevention measures to contain the occurrence and spread of multidrug resistance.

Materials and Methods {#s1}
=====================

Bacterial Strains and Susceptibility Test
-----------------------------------------

During 2012 to 2015, 450 clinical *S. maltophilia* isolates were collected from hospitalized patients at Peking Union Medical College Hospital, the Chinese PLA General Hospital, and the Air Force General Hospital in Beijing, China. Tigecycline is classified as a special-use antibacterial drug in China and is approved only for the treatment of complicated skin and soft-tissue infections, complicated intra-abdominal infections, and bacterial pneumonia. These *S. maltophilia* strains were all isolated from respiratory tract specimens of patients with pulmonary infection. Bacterial species identification was performed using a Vitek II bacterial identification system (bioMérieux, Marcy-l'Étoile, France), and the results were further confirmed by species-specific PCR ([@B41]). MIC results for SXT, minocycline, levofloxacin, ticarcillin/clavulanate, ceftazidime, and chloramphenicol were performed by the agar dilution method, and the results were interpreted according to the breakpoints suggested by [@B11]. Since there were no specified breakpoints criterion of tigecycline and doxycycline for *S. maltophilia*, tigecycline susceptibility breakpoint criterion for *Enterobacteriaceae* and doxycycline susceptibility breakpoint criterion for *Acinetobacter* spp. were used. *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 purchased from the American Type Culture Collection (Manassas, VA, United States) were used as quality control strains. SXT, minocycline, levofloxacin, ticarcillin/clavulanate, ceftazidime, and chloramphenicol were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Tigecycline and moxifloxacin were obtained from Wyeth Pharmaceutical (Philadelphia, PA, United States) and Bayer Healthcare (Bayer Pharma AG, Wuppertal, Germany), respectively. Mueller-Hinton agar was purchased from Becton Dickinson and Co. (Franklin Lakes, NJ, United States). Antimicrobial solutions were prepared fresh on the day of use as previously described ([@B11]).

Detection of Tetracycline-Specific Genes
----------------------------------------

Of the 450 isolates detected, 48 TNS and 48 TSS *S. maltophilia* were selected randomly and screened by PCR reaction for the presence of eight tetracycline-specific resistance genes (*tetA*, *tetB*, *tetM*, *tetH*, *tet39*, *tetX*, *tetX1*, and *tetX2*) using specific primers (**Table [1](#T1){ref-type="table"}**) and Taq DNA Polymerase (TaKaRa Bio, Tokyo, Japan). PCR cycling parameters were as follows: initial activation at 95°C for 5 min; 30 amplification cycles at 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s; and a final extension step at 72°C for 7 min. A 50-μL reaction volume was used, and the products were separated by 1% (w/v) agarose gel electrophoresis (Amresco, Solon, OH, United States) followed by ethidium bromide staining. Images were acquired using a Gel Doc^TM^ EQ imaging system (Bio-Rad, Hercules, CA, United States).

###### 

Primers used for specific amplification of tetracycline-specific resistance genes and intrinsic multidrug-resistance efflux pumps of *S. maltophilia.*

  Primer name   Sequence (5′--3′)         Origin                        Purpose
  ------------- ------------------------- ----------------------------- ------------------------------------------------
  tetA-F        CGTAATTCTGAGCACTGTC       ^∗^Access number: AY196695    PCR for *tetA*
  tetA-R        GTTGCATGATGAAGAAGACC                                    
  tetB-F        GTGGAACTGACAACTTGTC       ^∗^Access number: JN247441    PCR for *tetB*
  tetB-R        CACTCAGTATTCCAAGCCT                                     
  tetH-F        GCTGATCACCGTATTAGATG      ^∗^Access number: 210972275   PCR for *tetH*
  tetH-R        TGTCCTATTGGCAACAAGC                                     
  tetM-F        CAAGCTATATCCTACAGCGA      ^∗^Access number: JF830611    PCR for *tetM*
  tetM-R        GCATACAGATATTCTCTGGA                                    
  tet39-F       CTCCTTCTCTATTGTGGCTA      ^∗^Access number: EU495993    PCR for *tet39*
  tet39-R       ATCCTGCCCATAGATAACC                                     
  tetQ-F        TAACCGAGAATCTGCTGTT       ^∗^Access number: 807867      PCR for *tetQ*
  tetQ-R        CGTCCAACAACTCATTGATA                                    
  tetX1-F       TCAGGACAAGAAGCAATGAA      \#[@B3]                       PCR for *tetX1*
  tetX1-R       TATTTCGGGGTTGTCAAACT                                    
  tetX2-F^†^    TTAGCCTTACCAATGGGTGT      \#[@B3]                       PCR for *tetX, X2*^†^
  tetX2-R^†^    CAAATCTGCTGTTTCACTCG                                    
  sme 27        TGCCAGCGACAGTGCAAAGGGTC   \#[@B32]                      PCR for *smeT* and smeD/smeT intergenic region
  sme 43        CCAGGATCATCGATCTGCC                                     
  smeA-F        GTCGACCTGGTACAGCA         ^∗^Access number: AM743169    qRT-PCR for *smeA*
  smeA-R        ACCTTAACCTGTGCCTTG                                      
  smeD-F        CGGTCAGCATCCTGATGGA       \#[@B16]                      qRT-PCR for *smeD*
  smeD-R        TCAACGCTGACTTCGGAGAACT                                  
  smeI-F        ACTGCGATGAACACCGTTACC     \#[@B16]                      qRT-PCR for *smeI*
  smeI-R        CACGTCACCCTGCTTCACTTC                                   
  smeO-F        CAGGAAAGTCCACTGTCGTTC     \#[@B16]                      qRT-PCR for *smeO*
  smeO-R        CACGTCGCCCTTCTTCAC                                      
  smeW-F        GCCCACACCATCTCGTTCCC      \#[@B8]                       qRT-PCR for *smeW*
  smeW-R        TAGCCGTTGCCGTTGCCC                                      
  smrA-F        TGGAAGTGGCGATGTTCGAT      ^∗^Access number: FJ481984    qRT-PCR for *smrA*
  smrA-R        CATGGCGCTTGAAGAAGTCG                                    
  16SrDNA-F     GACCTTGCGCGATTGAATG       \#[@B8]                       qRT-PCR for *smeA*
  16SrDNA-R     CGGATCGTCGCCTTGGT                                       

qRT-PCR, quantitative real-time PCR.

∗

These primers were designed in this study and the gene sequence access number of reference strain were presented.

\#

These primers were cited from other studies and the reference information were presented in reference section. aaaTetX2-F and tetX2-R could amplify both tetX and tetX2 genes.

Detection of Expression of Intrinsic Multidrug Efflux Pumps
-----------------------------------------------------------

The expression levels of six multidrug efflux pump genes (*smeA*, *smeD*, *smeI*, *smeO*, *smeV*, and *smrA*) were assessed by real-time PCR using specific primers (**Table [1](#T1){ref-type="table"}**). *S. maltophilia* suspensions were prepared and inoculated in Mueller-Hinton broth (Difco, Cockeysville, MD, United States). After overnight culture, total DNase-treated RNA was extracted using the RNeasy kit (Tiangen, Beijing, China). cDNA was synthesized using the primeScript RT-PCR kit (TaKaRa Bio) following the manufacturer's instructions. Real-time PCR was performed using the DNA Engine Opticon 2 real-time PCR detection system (Bio-Rad) and a SYBR premix EX Taq kit (TaKaRa Bio). Thermocycling conditions were as follows: Taq activation at 95°C for 5 s, followed by 40 cycles at 95°C for 15 s and 58°C for 30 s. Each real-time PCR reaction was conducted in triplicate. Analysis of real-time PCR results was carried out by the 2^-ΔΔC~T~^ method. The housekeeping gene 16S rDNA was used as an internal control to normalize the expression of target genes and a susceptible *S. maltophilia* from Air Force General Hospital (K106, MIC~tigecycline~ = 0.25 mg/L) was used as an external control to normalize the relative expression levels of target genes from clinical isolates. All real-time PCR experiment amplifying the target gene should also include real-time PCR reaction amplifying 16S rDNA gene for both test strains and external control K106 in the same plate. The *C*~t~ values for the 16S rRNA gene in K106 were all within one cycle for each experiment under all conditions tested.

Amplification for *smeT* and *smeT/D* Intergenic Region
-------------------------------------------------------

To identify the sequence variations of the *smeT* and the *smeT/D* intergenic region, PCR reactions were performed using primers *sme* 27 and *sme* 43 presented by [@B32]; **Table [1](#T1){ref-type="table"}**). The primers were designed for sequence amplification of the *smeT* and the *smeT/D* intergenic region in D457R (accession number: [AJ316010](AJ316010)). The *S. maltophilia* K279a and ATCC13637 were used as control to ensure the accuracy of the PCR reaction. Sequence of the *smeT* and the *smeT/D* intergenic region of D457R were blasted in NCBI database^[1](#fn01){ref-type="fn"}^. All sequence of *smeT* gene and *smeT/D* intergenic region presented in NCBI database were downloaded and aligned in Mega 6.

Statistical Analyses
--------------------

SPSS 22.0 (SPSS Inc., Chicago, IL, United States) was used for statistical analyses. Comparative analyses of antimicrobial susceptibility rate and detection rate of tetracycline-specific resistant genes were performed by the Chi-squared test or Fisher's exact test, as appropriate. Expression levels of intrinsic multidrug-resistance efflux pumps are presented as median (interquartile range) and compared by Mann-Whitney *U* test. All comparisons were two-tailed, and *P* \< 0.05 was considered to indicate statistically significant differences.

Results
=======

Antimicrobial Susceptibility Profiles
-------------------------------------

Tigecycline exhibited good activity (MIC~50~/MIC~90~: 1/8 mg/L, susceptibility rate: 77.78%) (**Table [2](#T2){ref-type="table"}**). SXT (87.56%), minocycline (98.44%), and ticarcillin/clavulanate (76.00%) retained high *in vitro* activity against clinical isolates of *S. maltophilia*, while ceftazidime (26.44%) and chloramphenicol (12.00%) exhibited poor activity. TSS strains displayed high susceptibility to minocycline (100.00%), SXT (89.71%), doxycycline (97.71%), levofloxacin (82.00%), and ticarcillin/clavulanate (76.86%), while the TNS strains displayed high susceptibility to minocycline (94.00%), SXT (80.00%), and ticarcillin/clavulanate (73.00%), but poor susceptibility to doxycycline (25.00%) and levofloxacin (17.00%). The susceptibility rate of TNS strains to doxycycline and levofloxacin was much lower than that of TSS strains (25.00% vs. 97.71% for doxycycline, *P* \< 0.001; 17.00% vs. 82.00% for levofloxacin, *P* \< 0.001).

###### 

*In vitro* susceptibility of 450 clinical isolates of *S. maltophilia* to eight clinically used antimicrobials.

                                      Total (*N* = 450)     TNS (*N* = 100)   TSS (*N* = 350)                                                                                                                                                           
  --------- ------------------------- --------------------- ----------------- ----------------- ------- ----------------------- ----------------------- ------- ------- ------- ------------------------- -------------------- -------- ------- ------- ---------
  TIG^†^    0.25--32                  1/8                   77.78             8.67              13.56                                                                                                                                                   
  MIN       0.125--16                 0.5/2                 98.44             0.89              0.67    1--16                   2/4                     94.00   4.00    2.00    0.125--2                  0.5/1                100.00   0.00    0.00    \<0.001
  DOX^\#^   0.5 ≥ 32                  2/8                   81.33             14.22             4.44    4 ≥ 32                  8/16                    25.00   61.00   14.00   0.5--32                   2/4                  97.71    0.86    4.83    \<0.001
  LEV       0.125 ≥ 32                2/16                  67.56             11.33             21.11   1 ≥ 32                  8/32                    17.00   17.00   66.00   0.125--32                 2/4                  82.00    9.71    24.02   \<0.001
  T/K       1 ≥ 128                   8/64                  76.00             15.78             8.22    1 ≥ 128                 8/128                   73.00   14.00   13.00   1 ≥ 128                   8/64                 76.86    16.29   20.49   0.426
  CET       2 ≥ 64                    64/\>64               26.44             9.33              64.22   2 ≥ 64                  64/ \> 64               25.00   7.00    68.00   2 ≥ 64                    64/\>64              26.86    10.00   85.71   0.710
  CHL       1 ≥ 64                    16/64                 12.00             38.00             50.00   8 ≥ 64                  32/128                  1.00    11.00   88.00   1 ≥ 64                    16/64                15.14    45.71   69.24   \<0.001
  SXT       (2.273/0.125)/(\>152/8)   (4.75/0.25)/(152/8)   87.56                               12.44   (4.75/0.25)/(\>152/8)   (4.75/0.25)/(\>152/8)   80.00           20.00   (2.273/0.125)/(\>152/8)   (4.75/0.25)/(76/4)   89.71            28.64   0.009

MIC, minimum inhibitory concentration; TNS, tigecycline-nonsusceptible S. maltophilia; TSS, tigecycline-susceptible S. maltophilia; S, susceptible; I, intermediate; R, resistant; CET, ceftazidime; CHL, chloramphenicol; DOX, doxycycline; LEV, levofloxacin; MIN, minocycline; T/K, ticarcillin/clavulanate; TIG, tigecycline; SXT, sulfamethoxazole/trimethoprim. aaaMIC breakpoint criteria of these antimicrobials for S. maltophilia refer to susceptible breakpoint criteria for Enterobacteriaceae published by

CLSI (2015)

;

\#

MIC breakpoint criteria of these antimicrobials for S. maltophilia refer to susceptible breakpoint criteria for Acinetobacter spp. published by

CLSI (2015)

.

Detection of Tetracycline-Specific Genes
----------------------------------------

We screened eight tetracycline-specific resistance genes (*tetA*, *tetB, tetM, tetH, tet39, tetX, tetX1*, and *tetX2*) in 48 selected clinical TNS and 48 TSS clinical *S. maltophilia* by routine PCR analysis. Only one *tetB* and two *tetH* genes in TNS and three *tetH* genes in TSS were detected, and the detection rate was not different between the two groups.

Expression of Intrinsic Multidrug Efflux Pumps
----------------------------------------------

Real-time PCR showed that the average relative expression levels \[median (interquartile range)\] of *smeA*, *smeD*, *smeI*, *smeO*, *smeW*, and *smrA* in TNS *S. maltophilia* were 7.47 (3.64, 16.93), 20.59 (11.53, 112.54), 0.41 (0.20, 2.85), 1.12 (0.30, 1.90), 2.99 (1.44, 6.03), and 1.46 (0.63, 3.57), respectively. The values in TSS *S. maltophilia* were 8.64 (3.42, 14.68), 2.07 (0.80, 4.96), 0.65 (0.23, 11.61), 1.26 (0.56, 2.10), 4.75 (1.86, 6.61), and 1.74 (0.92, 2.96), respectively. Quantitative analysis (**Figure [1](#F1){ref-type="fig"}**) revealed that the average expression level of *smeD* was higher in the TNS group than in the TSS group \[20.59 (11.53, 112.54) vs. 2.07 (0.80, 4.96), *P* \< 0.001\]. We further divided the 98 selected *S. maltophilia* into levofloxacin-susceptible and levofloxacin-nonsusceptible strains (including 47 LSS and 49 LNS), doxycycline-susceptible and doxycycline-nonsusceptible strains (including 50 DSS and 46 DNS). Compared with that in the corresponding LSS and DSS, the expression of *smeD* was higher in LNS \[16.46 (5.83, 102.24) vs. 2.72 (0.80, 6.25), *P* \< 0.001\] and DNS \[19.69 (8.07, 115.10) vs. 3.01(1.00, 6.03), *P* \< 0.001\] (**Table [3](#T3){ref-type="table"}**).

![Real-time PCR analysis of intrinsic multidrug-resistance efflux pumps gene expression profiles in tigecycline-nonsusceptible and tigecycline-susceptible *S. maltophilia*. **(A--F)** Represent the relative expression level of *smeA, smeD, smeI, smeO, smeW*, and *smrA*, respectively. TNS, tigecycline-nonsusceptible *S. maltophilia*; TSS, tigecycline-susceptible *S. maltophilia*. Each dot corresponds to a clinical isolate. Expression levels of intrinsic multidrug-resistance efflux pumps are presented as median (interquartile range) and compared by non-parametric tests. ^∗∗∗^*P* \< 0.001.](fmicb-09-00549-g001){#F1}

###### 

Expression levels of intrinsic multidrug-resistance efflux pumps genes in *S. maltophilia* nonsusceptible to doxycycline or levofloxacin and the corresponding susceptible controls.

  Efflux pump genes   DOX                   LEV                                                                        
  ------------------- --------------------- -------------------- --------- ---------------------- -------------------- ---------
  *smeA*              7.14 (3.86, 15.1)     8.99 (3.47, 17.79)   0.477     7.11 (3.52, 14.76)     9.21 (3.66, 17.98)   0.343
  *smeD*              19.69 (8.07, 115.1)   3.01 (1.00, 6.03)    \<0.001   16.46 (5.83, 102.24)   2.72 (0.8, 6.25)     \<0.001
  *smeI*              0.43 (0.24, 1.68)     0.65 (0.18, 14.37)   0.797     0.42 (0.24, 2.85)      0.51 (0.2, 11.61)    0.843
  *smeO*              1.15 (0.46, 2.01)     1.29 (0.46, 2.05)    0.726     1.12 (0.42, 1.82)      1.29 (0.47, 2.14)    0.495
  *smeW*              3.51 (1.63, 5.79)     4.75 (1.64, 6.52)    0.511     3.65 (1.64, 6.3)       4.74 (1.63, 6.48)    0.742
  *smrA*              1.46 (0.63, 3.47)     1.74 (0.88, 3.01)    0.458     1.46 (0.55, 3.49)      1.74 (0.95, 2.9)     0.458

DOX, doxycycline; DNS, doxycycline-nonsusceptible S. maltophilia; DSS, doxycycline-susceptible S. maltophilia; LEV, levofloxacin; LNS, levofloxacin-nonsusceptible S. maltophilia; LSS, levofloxacin-susceptible S. maltophilia. Numbers denote median values and interquartile ranges.

Amplification for *smeT* and *smeT/D* Intergenic Region
-------------------------------------------------------

Primers *sme* 27 and *sme* 43, which designed for amplification of D457R failed to amplify the target gene in most of our clinical strains, and even the K279a and ATCC13637. The sequence of D457R (accession number: AJ316010) had 90--100% identity in *smeT* gene and 83--100% identity in *smeT/D* intergenic region with sequences of *S. maltophilia* strains from NCBI database. There was a variety of sequence variants located on the *smeT* and *smeT/D* intergenic region, including original and terminal region of these genes (see Supplementary Material).

Discussion
==========

*Stenotrophomonas maltophilia* is one of the leading multidrug resistant organisms in hospital settings and can cause severe nosocomial respiratory and bloodstream infections ([@B25]; [@B6]; [@B7]). Tigecycline is regarded as a potential alternative antimicrobial for infection treatment ([@B25]; [@B7]). Clinical isolates of *S. maltophilia* in Beijing showed good *in vitro* susceptibility to tigecycline. The tigecycline susceptibility rate in Beijing was lower than that reported in the Taiwan Surveillance of Antimicrobial Resistance Study from 1998 to 2008 and in the countries in the SENTRY Antimicrobial Surveillance Program from 2009 to 2012, but similar to that reported in SENTRY from 2011 to 2014 ([@B42]; [@B29], [@B28]). The difference might be partially due to the different geographic origins of the sources and the timing of the studies. More selective pressure caused by the gradual increase in the use of tigecycline in recent years might also contribute to the lower susceptibility rate. The clinical *S. maltophilia* isolates from Beijing showed high *in vitro* susceptibility to minocycline, SXT, and ticarcillin/clavulanate, rendering these compounds appropriate antimicrobial treatments for *S. maltophilia* infection in this area. Ceftazidime and chloramphenicol had poor activity, and they should not be used as empirical treatment. The susceptibility rate against doxycycline and levofloxacin in TNS *S. maltophilia* was much lower than that in the TSS group. Highly consistent antimicrobial resistance profiles against tigecycline, doxycycline, and levofloxacin indicated that they might share common genetic resistance determinants, and this criterion should be taken into account when deciding on the treatment regimen.

Due to the global spread of carbapenem-resistant *A. baumannii*, KPC-producing *K. pneumoniae*, and SXT-resistant *S. maltophilia*, tigecycline is regarded as the last resort in the control of clinical infections ([@B36]; [@B35]; [@B14]; [@B7]; [@B19]). Epidemiological investigations have demonstrated that overexpression of the RND efflux pump AdeABC plays the predominant role on the tigecycline resistance in clinically isolated *A. baumannii*, while the RND efflux pump AdeIJK and flavin-dependent monooxygenase TetX1 are also involved in tigecycline resistance ([@B14]; [@B22]). In *K. pneumonia*, the RND efflux pump AcrAB contributes to tigecycline resistance in clinical isolates ([@B4]; [@B19]). Tigecycline is not effective against *Pseudomonas aeruginosa*, and the reduced susceptibility is attributed to RND efflux pump MexXY ([@B13]; [@B35]). However, the tigecycline resistance mechanism in clinical isolates has not been fully elucidated. To identify the predominant genetic determinants of tigecycline resistance in clinical isolates of *S. maltophilia*, we compared the detection rate of eight tetracycline-specific resistance genes and the expression levels of six multidrug-resistance efflux pump genes. Among the eight tetracycline-specific resistance genes, only a few *tetB* or *tetH* genes were detected in clinical *S. maltophilia* isolates, and the detection rate was not different between the *TNS* and *TSS* groups, indicating that the tetracycline-specific resistance genes were not the predominant tigecycline resistance mechanism.

Regarding the intrinsic efflux pump genes, a variety of efflux pumps have been shown to be associated with resistance to tigecycline or tetracycline by the genetic introduction, deletion, or mutation in a single reference or clinical strain, including SmeDEF, SmeIJK, SmeOP-TolCsm, SmeVW, and SmrA ([@B2]; [@B44]; [@B1]; [@B9]; [@B18]; [@B24]; [@B31]). Considering the common resistance profile between tigecycline and levofloxacin, we also detected the expression level of *smeABC*, which could mediate the extrusion of quinolones ([@B23]). Quantitative analysis revealed that the average expression level of *smeD* was higher in TNS *S. maltophilia* than in TSS strains, while the remaining five intrinsic multidrug efflux genes did not show significant differences. The results indicate that overexpression of *smeDEF* is the predominant tigecycline resistance mechanism of clinical *S. maltophilia* isolates in Beijing. SmeDEF was identified as a novel multidrug efflux pump from *S. maltophilia* in 2000. The pump is formed by an inner membrane protein (SmeE), an outer membrane protein (SmeF), and a membrane fusion protein (SmeD) ([@B2]). [@B44] have identified tigecycline as a substrate of SmeDEF in both intrinsic and acquired resistance by genetic deletion and mutation of ULA-511 strain. We confirmed that overexpression of *smeDEF* is the common genetic determinants of resistance to tigecycline in clinical isolates of *S. maltophilia* in Beijing. Subsequent studies after [@B44] demonstrated that this pump mediated not only multiple resistance to a variety of structurally unrelated antimicrobial agents, but also a number of disinfectants and heavy-metal ions ([@B32]; [@B17]; [@B7]). A battery of epidemiological investigations have indicated that quinolone resistance in clinical isolates of *S. maltophilia* is associated with overexpression of *smeDEF*, and the extrusion activity of SmeDEF is not abolished by the efflux pump inhibitor Phe-Arg-β-naphthylamide ([@B32]; [@B21]; [@B10]). We further compared the expression levels of intrinsic efflux pumps between levofloxacin-nonsensitive and levofloxacin-sensitive, and doxycycline-nonsensitive and doxycycline-sensitive groups. The results revealed a higher expression of *smeD* in levofloxacin- and doxycycline-nonsensitive isolates than in their corresponding sensitive counterparts, which demonstrated that overexpression of SmeDEF is also the common genetic determinants of multiple resistance to doxycycline, and levofloxacin.

Our results highlight the importance of the rational use of antibiotics to prevent the emergence and spread of multidrug resistance. Due to a variety of intrinsic and acquired antimicrobial resistance mechanisms, therapeutic options for *S. maltophilia* treatment are limited, especially for patients who cannot tolerate SXT. Tigecycline, doxycycline, and levofloxacin have become the few available potential alternative antimicrobial agents when SXT is unsuitable for the treatment of *S. maltophilia* owing to contraindications or resistance. However, inappropriate use and overuse of tigecycline might result in the occurrence and spread of tigecycline, and also the emergence of resistance to levofloxacin and doxycycline. A serendipitous mutation in the regulatory *smeT* gene, such as A/T mutation at position 498, could lead to overexpression of *smeDEF* and multiple resistances to tigecycline, doxycycline, and levofloxacin ([@B32]). If clinical strains with this mutation were selected and enriched by pressure of prolonged exposure to subinhibitory concentrations, the selection and enrichment would result in emergence of multidrug resistance and the failure of clinical treatment. Using primers *sme* 27 and *sme* 43 presented by [@B32], we tried to identify other sequence variations located on the *smeT* and the *smeT/D* intergenic region in clinical *S. maltophilia*, but the primers designed for amplification of D457R failed to amplify most of our clinical strains, and even the K279a and ATCC13637. We further downloaded all of the sequence of *smeT* and the *smeT/D* intergenic region in NCBI database and performed sequence alignment. The result of alignment revealed a variety of sequence variants located on the *smeT* and *smeT/D* intergenic region, including original and terminal region of these genes, therefore it was difficult to design general primers that could amplify the complete sequence of *smeT* in clinical *S. maltophilia* from different areas and times. Further researches are still needed to identify the possible sequence variations of *smeT* gene leading to the overexpression of *smeDEF* in clinical scenario.

Conclusion
==========

Clinical isolates of *S. maltophilia* in Beijing showed good *in vitro* susceptibility to tigecycline. *S. maltophilia* had highly consistent antimicrobial resistance profiles against tigecycline, doxycycline, and levofloxacin, and the *smeDEF* efflux pumps gene was the common genetic determinant of resistance to these three drugs. The consistent resistance profile and common resistance genetic determinant highlight the importance of rational use of tigecycline for preventing the occurrence and spread of multidrug resistance.
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